BTG (NASDAQ:BTGGF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

According to Zacks, “BTG plc is a healthcare company. Its operating segment consists of Interventional Medicine and Specialty Pharmaceuticals. Interventional Medicine offers treatment of cancer, severe emphysema, severe blood clots and varicoseveins. Specialty Pharmaceuticals helps patients overexposed to certain medications or toxins. BTG plc is headquartered in London, the United Kingdom. “

BTG (NASDAQ:BTGGF) opened at 9.2205 on Friday. BTG has a 1-year low of $6.74 and a 1-year high of $9.35. The company has a market capitalization of $3.55 billion and a PE ratio of 81.5973. The company has a 50 day moving average of $8.74 and a 200 day moving average of $8.34.

ILLEGAL ACTIVITY WARNING: “BTG (BTGGF) Rating Lowered to Hold at Zacks Investment Research” was first published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/24/btg-btggf-rating-lowered-to-hold-at-zacks-investment-research.html.

Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.